VIR-2482
VIR-2482 is a monoclonal antibody targeting influenza A hemagglutinin (HA). VIR-2482 is generated by introducing LS mutations (M428L/N434S) into the Fc region of MEDI8852 (HY-P991446). VIR-2482 binds to the conserved HA stem epitope across all 18 influenza A HA subtypes, neutralizes a broad spectrum of H1N1 and H3N2 strains, binds to FcγRIIIa, FcγRIIa and C1q, and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. VIR-2482 reduces morbidity and mortality caused by seasonal influenza A strains and provides prophylactic protection in mice. VIR-2482 can be used in research related to influenza A disease.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
VIR-2482 shows that influenza A virus isolates from study participants retain susceptibility to it in vitro, with fold changes in EC50 ranging from 0.23 to 2.55 relative to subtype reference strains[1].
VIR-2482 binds to all 18 influenza A HA subtypes and neutralizes a broad panel of H1N1 and H3N2 viruses spanning nearly 100 years of evolution, with key contact residues showing >98.8% conservation in H1N1 and H3N2 sequences from 2009-2019[2].
VIR-2482 retains the ability to engage human FcγRIIIa, FcγRIIa, and C1q, and maintains functional ADCC and CDC activity in vitro despite containing half-life extending Fc mutations[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
influenza A virus hemagglutinin HA
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Tan SK, et al. A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA). Clin Infect Dis. 2024;79(4):1054-1061. [Content Brief]
[3]. Plotnik D, et al. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrob Agents Chemother. 2024;68(4):e0127323. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)